RecruitingNCT06655883
Suvorexant for insomnia in people with opioid use disorder
About this title
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
Read the official source — NCT06655883Researchers are comparing Suvorexant and placebo, tracking side effects to assess safety in people with opioid dependence.
Medication studyAges 18–70United StatesAddiction
Understand this study
What is this study about?
Researchers are comparing Suvorexant and placebo, tracking side effects to assess safety in people with opioid dependence.
Who could participate?
This study is for people with insomnia. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
What will I do during this study?
Participants take suvorexant or a matching placebo (an inactive comparison treatment) at night for up to about eight weeks. In the suvorexant group, the dose starts at 10 mg for three nights and may then increase to 20 mg nightly, depending on the investigator’s decision.
- Listed locations
- Garden Grove and 12 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Participation duration
- Up to about 8 weeks
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 9, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 300
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT06655883
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Suvorexant for the Treatment of Insomnia in Participants With Opioid Use Disorder
Recruitment & locations
RecruitingGarden Grove · New Haven · Bradenton
10 more locations
- Savannah
- Baltimore
- Marlton
- Oklahoma City
- Philadelphia
- Providence
- Charleston
- DeSoto
- Houston
- Richmond
A listed location does not confirm current availability.
Questions about this study
What is this study about?
Researchers are comparing Suvorexant and placebo, tracking side effects to assess safety in people with opioid dependence.
Who is behind this study?
The study sponsor is Merck Sharp & Dohme LLC.
Does this study involve medication?
Yes. The study involves medication, including Suvorexant and Placebo.
Who can participate?
This study is for people with insomnia. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
